US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chromocell Therapeutics Corp.

1.25

+0.11009.65%

Post-market: 1.12-0.1300-10.40%19:46 EDT

Volume:71.23K

Turnover:85.28K

Market Cap:7.63M

PE:-0.88

High:1.28

Open:1.21

Low:1.06

Close:1.14

Loading ...

Overview Company News Filings

Chromocell Therapeutics Faces Going Concern Disclosure

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

Gildan Reports Results for the First Quarter of 2025; Maintains Full Year Guidance

The longtime CHRO of Citizens Bank says that HR teams treat corporate initiatives like ‘diet fads’ and argues that making real changes can take years of consistency

Press Release: Angie DeWitt announces her retirement from Associated Bank

LGND: Pelthos To Become Public Company

Zacks Small Cap Research

Press Release: SJW Group Appoints Kay R. New as Chief Human Resources Officer

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings

Dow Falls Over 1%; US Initial Jobless Claims Decline

Ligand to Combine Pelthos Unit With Channel Therapeutics

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

MT Newswires Live

BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics

Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics

THOMSON REUTERS

Channel Therapeutics Corp - Upon Completion of Deal, Plesha to Become CEO of Combined Co and Knuettel to Become CFO

THOMSON REUTERS

Channel Therapeutics Corp - Proposed Transaction Will Raise $50 Mln in Equity Capital

THOMSON REUTERS

Channel Therapeutics Corp -Combined Co to Operate Under Name Pelthos Therapeutics Inc., Trade on Nyse American Exchange Under Ticker Pths

THOMSON REUTERS

Channel Therapeutics Corp - Ligand Is Entitled to a 13% Royalty on Worldwide Sales of Zelsuvmi

THOMSON REUTERS

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Rotork CHRO Acquires Company Shares, Signaling Market Confidence

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHRO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHRO\",,,,,undefined,":{"symbol":"CHRO","market":"US","secType":"STK","nameCN":"Chromocell Therapeutics Corp.","latestPrice":1.25,"timestamp":1746129600000,"preClose":1.14,"halted":0,"volume":71233,"hourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.25,"latestTime":"19:46 EDT","volume":753,"amount":877.9144,"timestamp":1746143213629},"delay":0,"floatShares":2510085,"shares":6103813,"eps":-1.427101,"marketStatus":"Closed","change":0.11,"latestTime":"05-01 16:00:00 EDT","open":1.21,"high":1.275,"low":1.0601,"amount":85283.2604821,"amplitude":0.188509,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.427101,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746172800000},"marketStatusCode":5,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":1.14,"preHourTrading":{"tag":"盘前","latestPrice":1.23,"preClose":1.14,"latestTime":"09:10 EDT","volume":324,"amount":385.4499696,"timestamp":1746105012495},"postHourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.25,"latestTime":"19:46 EDT","volume":753,"amount":877.9144,"timestamp":1746143213629},"volumeRatio":0.933689},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHRO\",,,,,undefined,":{"symbol":"CHRO","floatShares":2510085,"roa":"-645.79%","roe":"-26.00%","lyrEps":-1.427101,"volumeRatio":0.933689,"shares":6103813,"dividePrice":0,"high":1.275,"amplitude":0.188509,"preClose":1.14,"low":1.0601,"week52Low":0.45,"pbRate":"-2.81","week52High":3.8,"institutionHeld":0,"latestPrice":1.25,"eps":-1.427101,"divideRate":0,"volume":71233,"delay":0,"ttmEps":-1.427101,"open":1.21,"prevYearClose":0.641,"prevWeekClose":1.36,"prevMonthClose":1.14,"prevQuarterClose":1.42,"fiveDayClose":1.37,"twentyDayClose":1.4494,"sixtyDayClose":1.72},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHRO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532391098","title":"Chromocell Therapeutics Faces Going Concern Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2532391098","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532391098?lang=en_us&edition=fundamental","pubTime":"2025-05-02 05:28","pubTimestamp":1746134886,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics Corp ( ($CHRO) ) has shared an announcement. Channel Therapeutics Corporation announced on May 1, 2025, that its audited fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-faces-going-concern-disclosure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-faces-going-concern-disclosure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","CHRO"],"gpt_icon":0},{"id":"2532831341","title":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2532831341","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532831341?lang=en_us&edition=fundamental","pubTime":"2025-05-02 05:00","pubTimestamp":1746133200,"startTime":"0","endTime":"0","summary":"FREEHOLD, N.J., May 01, 2025  -- Channel Therapeutics Corporation, , , a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph.Release of this information is required by Sections 410 and 610 of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company's consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/channel-therapeutics-provides-announcement-2024-210000563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CHRO","NYSE","BK4117","LENZ","AFG","BK4007","BK4107"],"gpt_icon":0},{"id":"2531144367","title":"Gildan Reports Results for the First Quarter of 2025; Maintains Full Year Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531144367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531144367?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:04","pubTimestamp":1745957040,"startTime":"0","endTime":"0","summary":" Please refer to \"Non-GAAP financial measures and related ratios\" in this press release. Net sales of $712 million, up 2.3% vs. the prior year. Operating margin of 18.2%, adjusted operating margin1 of 19.0%. GAAP diluted EPS of $0.56 and adjusted diluted EPS1 of $0.59. Capital returned to shareholders of $62 million through share repurchases. Company maintains its full year 2025 guidance, including the impact of tariffs. MONTREAL, April 29, 2025  -- Gildan Activewear Inc.  today announced results for the first quarter ended March30, 2025 and maintained its 2025 guidance.The Company generated gross profit of $222 million, or 31.2% of net sales, versus $211 million, or 30.3% of net sa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gildan-reports-results-first-quarter-200400228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GSG","ESG","GIL","BK4202","CHRO","BK4139"],"gpt_icon":0},{"id":"2530159380","title":"The longtime CHRO of Citizens Bank says that HR teams treat corporate initiatives like ‘diet fads’ and argues that making real changes can take years of consistency","url":"https://stock-news.laohu8.com/highlight/detail?id=2530159380","media":"Fortune","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530159380?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:29","pubTimestamp":1745584198,"startTime":"0","endTime":"0","summary":"CHROs are often inundated with requests across the management team, she says, leading them to treat new initiatives like new “diet fads.” That means discarding them when they either don’t work as expected, or getting bored and wanting to move onto the next big thing. But she emphasizes that it pays for HR to focus on what’s most important for the long-term growth of the company.That’s something she experienced first hand, especially after helping the organization transition into becoming a public company in 2014. At the time, the demands on her team were significant, and she says it felt as if there were “100 different agendas coming in all at once.”“If you try to overhaul an entire culture or talent strategy overnight, you may get flash in the pan results,” she says. “But to get what you really want, true change, it takes consistency, alignment, and also narrowing your focus.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/longtime-chro-citizens-bank-says-122958524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0106831901.USD","BK4588","BK4211","HR","BK4585","LU0949170772.SGD","LU2237438978.USD","CHRO","LU0738911758.USD","BK4203","LU1668664300.SGD","BK4225","LU0661504455.SGD","BK4139","CFG"],"gpt_icon":0},{"id":"2529683788","title":"Press Release: Angie DeWitt announces her retirement from Associated Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2529683788","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529683788?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:05","pubTimestamp":1745413500,"startTime":"0","endTime":"0","summary":"DeWitt set to step down as chief human resources officer on June 2, 2025. GREEN BAY, Wis., April 23, 2025 /PRNewswire/ -- Associated Banc-Corp   today announced that Chief Human Resources Officer  Angie DeWitt has announced her plans to retire after an exceptional 17-year career with the company.Joining Associated Bank in 2008, DeWitt has been a key member of the bank's executive leadership team, playing a pivotal role in shaping organizational success. She began her career in Finance and advanced to the position of CHRO in 2019.\"Angie's career is a true success story, one that we proudly celebrate,\" said President & CEO Andy Harmening. \"She has been a trusted partner to me since day one. Her legacy is one of lasting impact, shaping not only the workforce we have today, but the foundation on which we'll build for years to come.\". DeWitt will remain with Associated for a period of time as an advisor to assure successful transition of her successor.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASB","CHRO","BK4211","BK4139"],"gpt_icon":0},{"id":"2529689290","title":"LGND: Pelthos To Become Public Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2529689290","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529689290?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:10","pubTimestamp":1745399400,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals, Inc.  announced that it had identified a suitor to take its subsidiary Pelthos Therapeutics public in an April 17thpress release. Ligand’s subsidiary will combine with the public company Channel Therapeutics  which is a clinical stage life sciences company developing pain therapeutics. Alongside the merger agreement, there will be a $50.1 million private investment in public equity  that is set to close just prior to the consummation of the merger. It will include an $18 million contribution from Ligand and $32 million from other investors.Readers may recall that Pelthos offers Zelsuvmi, an FDA approved treatment for molluscum contagiosum. Since the acquisition of Novan by Ligand in 2023, Zelsuvmi has received FDA approval, Pelthos was created and CEO was appointed to the company. In the last few quarters, Pelthos has been building inventory and preparing for commercial launch. Now that the pathway to being public has been clarified, Pelthos is interacting with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgnd-pelthos-become-public-company-091000998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1878469433.USD","CHRO","BK4007","BK4127","LU1559883803.SGD","LGND","LU0566484027.USD","MC","PIPE","BK4139"],"gpt_icon":0},{"id":"2529016008","title":"Press Release: SJW Group Appoints Kay R. New as Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529016008","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529016008?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:15","pubTimestamp":1745241300,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., April 21, 2025  -- SJW Group , a leading national investor-owned pure-play water and wastewater utility, today announced that its board of directors has appointed Kay R. New as chief human resources officer , effective immediately. In her new role, New will oversee enterprise-wide efforts related to talent development, organizational effectiveness, employee engagement and performance.\"Kay is an outstanding utility executive whose experience uniting teams, building high-performance cultures, and leading employee-focused initiatives at a national scale makes her an ideal fit for SJW Group,\" stated Eric W. Thornburg, chair, president and chief executive officer. \"Her deep expertise in human resources strategy, business acumen, and purposeful leadership will further strengthen our ability to empower teams, enhance performance, and deliver on our mission to provide high-quality water and exceptional service to our communities.\". SJW Group is among the largest investor-owne","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRO","BK4172","SJW","BK4139"],"gpt_icon":0},{"id":"2528728424","title":"Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2528728424","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528728424?lang=en_us&edition=fundamental","pubTime":"2025-04-18 00:09","pubTimestamp":1744906149,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44870357/gold-falls-over-1-dr-horton-posts-downbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADGM","CHRO","CWD","RTC","LGND","DHI","GPN"],"gpt_icon":1},{"id":"2528745870","title":"Dow Falls Over 1%; US Initial Jobless Claims Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2528745870","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528745870?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:58","pubTimestamp":1744898299,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6a27bb69de7b77a624049dad1cefcd82","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44864892/dow-falls-over-1-us-initial-jobless-claims-decline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4130","USJW.SI","CWD","LU0566484027.USD","QID","IOTR","PSQ","NVIW.SI","BK4082","CHRO","BK4135","RTC","BK4007","ADGM","QLD","BK4090","NQmain","BK4023",".IXIC","TSYW.SI","MNQmain","TQQQ","USAW.SI","BK4139","LU1559883803.SGD","LGND","CLIK","SQQQ"],"gpt_icon":1},{"id":"2528418713","title":"Ligand to Combine Pelthos Unit With Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528418713","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528418713?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:31","pubTimestamp":1744889460,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum contagiosum infections.Ligand on Thursday said it will invest $18 million in the combined company, which will operate as Pelthos Therapeutics, while a group led by investment firm Murchinson will chip in an additional $32 million.Channel, a Freehold, N.J., clinical-stage biotechnology company that had a market capitalization of around $7.7 million based on Thursday's closing share price of $1.26, said its shareholders will own about 7.7% of the combined company, while Ligand will own about 55% and the other investors will own roughly 37%.Channel shares were recently up nearly 20% at $1.50 in premarket trading.The U.S. Food and Drug Administration in January 2024 approved Zelsuvmi as the first novel drug for the treatment of molluscum contagiosum, a highly contagious viral skin infection.Jupiter, ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CHRO","LU0566484027.USD","LU1559883803.SGD","LGND","BK4007","BK4139"],"gpt_icon":0},{"id":"2528923527","title":"Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528923527","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528923527?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:37","pubTimestamp":1744886232,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals  and Channel Therapeutics  said Thursday they have agreed to merge Ligand's Pelthos Therapeutics and LNHC subsidiaries with Channel's CHRO Merger Sub in a deal worth $50 million.Upon the expected summer 2025 completion of the transaction, the new company will operate under the name Pelthos Therapeutics and trade on the New York Stock Exchange under the ticker symbol \"PTHS,\" the companies said.The merger will be backed by $50 million in capital raised from a group of investors that includes Ligand and a group of investors led by Murchinson, the companies said.The new company will initially focus on commercializing Pelthos' US Food and Drug Administration-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum, a contagious skin infection, the companies said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0566484027.USD","LU1559883803.SGD","LGND","BK4139","LENZ","CHRO","BK4007"],"gpt_icon":0},{"id":"2528791843","title":"BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528791843","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528791843?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:06","pubTimestamp":1744884371,"startTime":"0","endTime":"0","summary":"BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel TherapeuticsApril 17 (Reuters) - Channel Therapeutics Corp CHRO.A:LIGAND SUBSIDIARY PELTHOS THERAPEUTICS TO COMBINE WITH CHANNEL TH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","CHRO","BK4139","LGND","BK4007","LU1559883803.SGD"],"gpt_icon":0},{"id":"2528993797","title":"Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528993797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528993797?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","BK4007","LU1559883803.SGD","LGND","LU0566484027.USD","BK4139"],"gpt_icon":0},{"id":"2528799951","title":"Channel Therapeutics Corp - Upon Completion of Deal, Plesha to Become CEO of Combined Co and Knuettel to Become CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799951","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799951?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","CHRO","LGND","BK4007","LU1559883803.SGD","BK4139"],"gpt_icon":0},{"id":"2528799530","title":"Channel Therapeutics Corp - Proposed Transaction Will Raise $50 Mln in Equity Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799530?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","LU1559883803.SGD","LU0566484027.USD","BK4139","BK4007","CHRO"],"gpt_icon":0},{"id":"2528612799","title":"Channel Therapeutics Corp -Combined Co to Operate Under Name Pelthos Therapeutics Inc., Trade on Nyse American Exchange Under Ticker Pths","url":"https://stock-news.laohu8.com/highlight/detail?id=2528612799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528612799?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","LGND","BK4007","LU0566484027.USD","BK4139","CHRO"],"gpt_icon":0},{"id":"2528582799","title":"Channel Therapeutics Corp - Ligand Is Entitled to a 13% Royalty on Worldwide Sales of Zelsuvmi","url":"https://stock-news.laohu8.com/highlight/detail?id=2528582799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528582799?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","BK4139","LU0566484027.USD","LGND","BK4007","LU1559883803.SGD"],"gpt_icon":0},{"id":"2528079969","title":"Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528079969","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528079969?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884000,"startTime":"0","endTime":"0","summary":"Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI. ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers. Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI. Frank Knuettel II, CEO of Channel Therapeutics, commented, “We are very excited about the merger with Pelthos. We have performed extensive due diligence on the ZELSUVMI market opportunity and their team and o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ligand-subsidiary-pelthos-therapeutics-combine-100000828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LGND","LU0566484027.USD","BK4007","CHRO","LU1559883803.SGD","LENZ"],"gpt_icon":0},{"id":"2528799676","title":"EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799676","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799676?lang=en_us&edition=fundamental","pubTime":"2025-04-17 17:45","pubTimestamp":1744883135,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Incorporated  and Channel Therapeutics Corporation  on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc.  with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel.The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson.Under the merger agreement, Channel will acquire 100% of Pelthos’ issued and outstanding equity interests, change its name to Pelthos Therapeutics, and trade on the NYSE American exchange under the ticker PTHS.Upon completing the transaction, Scott Plesha, CEO of Pelthos, will become CEO of the combined company, and Frank Knuettel II, CEO of Channel Therapeutics, will become CFO. The transaction is expected to close in the summer of 2025.The combined company will initially focus on accelerating the commercialization of Pelthos’ Zelsuvmi  topical gel, 10.3%, for Molluscum contagiosum infections in adu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-ligand-subsidiary-pelthos-therapeutics-094535653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","LENZ","MDCO","LU0566484027.USD","CHRO","LGND","LU1559883803.SGD"],"gpt_icon":0},{"id":"2526955006","title":"Rotork CHRO Acquires Company Shares, Signaling Market Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2526955006","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526955006?lang=en_us&edition=fundamental","pubTime":"2025-04-11 22:03","pubTimestamp":1744380189,"startTime":"0","endTime":"0","summary":"Rotork plc ( ($GB:ROR) ) just unveiled an update. Rotork plc announced that Beatriz Rodriguez Gomez, the Chief Human Resources Officer, has purchas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rotork-chro-acquires-company-shares-signaling-market-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rotork-chro-acquires-company-shares-signaling-market-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHRO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHRO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHRO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CHRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CHRO","date":"2025-04-30","current":-0.982093,"percent":0.429078,"low":-7.431441,"twenty":-1.409573,"median":-0.923265,"eighty":-0.420047,"high":-0.323812,"avg":-1.256968,"sd":1.263875,"marketCap":7812880},"quantilePoints":[{"date":"2024-02-16","current":-7.431441,"twenty":-7.431441,"median":-7.431441,"eighty":-7.431441,"marketCap":34177704},{"date":"2024-02-23","current":-6.019507,"twenty":-6.301894,"median":-5.994425,"eighty":-5.828056,"marketCap":27684120},{"date":"2024-03-01","current":-4.727821,"twenty":-5.999441,"median":-5.629076,"eighty":-4.958568,"marketCap":21743569},{"date":"2024-03-08","current":-4.539711,"twenty":-5.86133,"median":-5.016255,"eighty":-4.479516,"marketCap":20878440},{"date":"2024-03-15","current":-4.238736,"twenty":-5.828056,"median":-4.640036,"eighty":-4.238736,"marketCap":19494234},{"date":"2024-03-22","current":-3.486297,"twenty":-5.509688,"median":-4.489549,"eighty":-4.100889,"marketCap":16033719},{"date":"2024-03-28","current":-3.398513,"twenty":-5.332279,"median":-4.32652,"eighty":-3.722062,"marketCap":15629992},{"date":"2024-04-05","current":-2.934509,"twenty":-5.11658,"median":-4.198982,"eighty":-3.225452,"marketCap":13496008},{"date":"2024-04-12","current":-2.295564,"twenty":-4.843195,"median":-4.100914,"eighty":-3.039851,"marketCap":10557454},{"date":"2024-04-19","current":-0.975552,"twenty":-4.712772,"median":-3.868787,"eighty":-2.801578,"marketCap":7200347},{"date":"2024-04-26","current":-1.194553,"twenty":-4.627495,"median":-3.486297,"eighty":-2.39777,"marketCap":8816752},{"date":"2024-05-03","current":-1.385682,"twenty":-4.55476,"median":-3.210403,"eighty":-1.424176,"marketCap":10227432},{"date":"2024-05-10","current":-1.409573,"twenty":-4.509614,"median":-3.084997,"eighty":-1.409573,"marketCap":10403767},{"date":"2024-05-17","current":-1.316144,"twenty":-4.459376,"median":-3.003483,"eighty":-1.403202,"marketCap":11814448},{"date":"2024-05-24","current":-0.929813,"twenty":-4.371616,"median":-2.871806,"eighty":-1.319641,"marketCap":8346525},{"date":"2024-05-31","current":-0.929813,"twenty":-4.291406,"median":-2.506623,"eighty":-1.259855,"marketCap":8346525},{"date":"2024-06-07","current":-0.969101,"twenty":-4.238736,"median":-2.385856,"eighty":-1.203901,"marketCap":8699195},{"date":"2024-06-14","current":-0.883977,"twenty":-4.222834,"median":-2.155189,"eighty":-1.121113,"marketCap":7935077},{"date":"2024-06-21","current":-1.014937,"twenty":-4.159228,"median":-1.641577,"eighty":-0.982197,"marketCap":9110644},{"date":"2024-06-28","current":-0.89046,"twenty":-4.155917,"median":-1.508981,"eighty":-0.975591,"marketCap":7993267},{"date":"2024-07-05","current":-0.818497,"twenty":-4.140944,"median":-1.441428,"eighty":-0.931673,"marketCap":7347293},{"date":"2024-07-12","current":-0.825045,"twenty":-4.100889,"median":-1.409653,"eighty":-0.924575,"marketCap":7406072},{"date":"2024-07-15","current":-0.753018,"twenty":-4.100864,"median":-1.409613,"eighty":-0.911479,"marketCap":6759510},{"date":"2024-08-02","current":-0.687538,"twenty":-4.100839,"median":-1.409573,"eighty":-0.898383,"marketCap":6171726},{"date":"2024-08-09","current":-0.448275,"twenty":-3.995448,"median":-1.389664,"eighty":-0.877429,"marketCap":4023965},{"date":"2024-08-16","current":-0.483077,"twenty":-3.8575,"median":-1.321973,"eighty":-0.848618,"marketCap":4731657},{"date":"2024-08-23","current":-0.510034,"twenty":-3.676915,"median":-1.282154,"eighty":-0.822426,"marketCap":4995695},{"date":"2024-08-30","current":-0.535762,"twenty":-3.526427,"median":-1.242336,"eighty":-0.784448,"marketCap":5247700},{"date":"2024-09-06","current":-0.544711,"twenty":-3.451183,"median":-1.217924,"eighty":-0.690157,"marketCap":5335354},{"date":"2024-09-13","current":-0.576739,"twenty":-3.353367,"median":-1.168814,"eighty":-0.569957,"marketCap":5649063},{"date":"2024-09-20","current":-0.512742,"twenty":-3.225452,"median":-1.086965,"eighty":-0.542874,"marketCap":5022222},{"date":"2024-09-27","current":-0.600525,"twenty":-3.130144,"median":-0.978923,"eighty":-0.535762,"marketCap":5882038},{"date":"2024-10-04","current":-0.40035,"twenty":-3.10757,"median":-0.969101,"eighty":-0.518359,"marketCap":3921358},{"date":"2024-10-11","current":-0.323812,"twenty":-3.074965,"median":-0.929813,"eighty":-0.510905,"marketCap":3171687},{"date":"2024-10-18","current":-0.453043,"twenty":-3.039851,"median":-0.929813,"eighty":-0.50063,"marketCap":4437478},{"date":"2024-10-25","current":-0.44745,"twenty":-3.004737,"median":-0.897073,"eighty":-0.496905,"marketCap":4382695},{"date":"2024-10-31","current":-0.387809,"twenty":-2.984671,"median":-0.887219,"eighty":-0.481006,"marketCap":3798527},{"date":"2024-11-08","current":-0.3768,"twenty":-2.921968,"median":-0.877429,"eighty":-0.4664,"marketCap":3690690},{"date":"2024-11-15","current":-0.384351,"twenty":-2.836692,"median":-0.854511,"eighty":-0.455716,"marketCap":3869549},{"date":"2024-11-22","current":-0.377927,"twenty":-2.658314,"median":-0.844689,"eighty":-0.443305,"marketCap":3804880},{"date":"2024-11-29","current":-0.365833,"twenty":-2.506623,"median":-0.825045,"eighty":-0.418071,"marketCap":3683114},{"date":"2024-12-06","current":-0.39577,"twenty":-2.470506,"median":-0.818497,"eighty":-0.40035,"marketCap":3984515},{"date":"2024-12-13","current":-0.412535,"twenty":-2.445424,"median":-0.753018,"eighty":-0.397566,"marketCap":4153299},{"date":"2024-12-20","current":-0.39098,"twenty":-2.326288,"median":-0.690812,"eighty":-0.394462,"marketCap":3936291},{"date":"2024-12-27","current":-0.395231,"twenty":-2.301709,"median":-0.659676,"eighty":-0.389674,"marketCap":3979090},{"date":"2025-01-03","current":-0.433118,"twenty":-2.127114,"median":-0.588632,"eighty":-0.388621,"marketCap":4360524},{"date":"2025-01-10","current":-0.604732,"twenty":-1.900137,"median":-0.571087,"eighty":-0.389195,"marketCap":6088291},{"date":"2025-01-17","current":-0.574794,"twenty":-1.658886,"median":-0.565435,"eighty":-0.389459,"marketCap":5786890},{"date":"2025-01-24","current":-1.670496,"twenty":-1.659719,"median":-0.576739,"eighty":-0.390022,"marketCap":16818150},{"date":"2025-01-31","current":-1.460936,"twenty":-1.611819,"median":-0.602629,"eighty":-0.391676,"marketCap":14708346},{"date":"2025-02-07","current":-0.946016,"twenty":-1.585135,"median":-0.66128,"eighty":-0.394604,"marketCap":9524257},{"date":"2025-02-14","current":-1.035827,"twenty":-1.538609,"median":-0.708819,"eighty":-0.395183,"marketCap":10428459},{"date":"2025-02-21","current":-0.975953,"twenty":-1.472911,"median":-0.759705,"eighty":-0.395231,"marketCap":9825657},{"date":"2025-02-28","current":-1.227426,"twenty":-1.46293,"median":-0.818497,"eighty":-0.39564,"marketCap":12357422},{"date":"2025-03-07","current":-1.261554,"twenty":-1.460936,"median":-0.821771,"eighty":-0.39577,"marketCap":12701019},{"date":"2025-03-14","current":-1.023852,"twenty":-1.460936,"median":-0.844689,"eighty":-0.397566,"marketCap":10307898},{"date":"2025-03-21","current":-0.880154,"twenty":-1.457355,"median":-0.854511,"eighty":-0.40035,"marketCap":8861176},{"date":"2025-03-28","current":-0.886141,"twenty":-1.4255,"median":-0.869975,"eighty":-0.40035,"marketCap":8921456},{"date":"2025-04-04","current":-1.077003,"twenty":-1.422191,"median":-0.878791,"eighty":-0.409475,"marketCap":8567922},{"date":"2025-04-11","current":-1.035801,"twenty":-1.409653,"median":-0.886141,"eighty":-0.412125,"marketCap":8240147},{"date":"2025-04-17","current":-0.962911,"twenty":-1.409589,"median":-0.89046,"eighty":-0.412453,"marketCap":7660285},{"date":"2025-04-25","current":-1.051146,"twenty":-1.409589,"median":-0.903563,"eighty":-0.416964,"marketCap":8362223},{"date":"2025-04-30","current":-0.982093,"twenty":-1.409573,"median":-0.923265,"eighty":-0.420047,"marketCap":7812880}],"updateTime":1746151821092}}}